On Monday, Aquestive Therapeutics Inc (NASDAQ: AQST) was -3.41% drop from the session before settling in for the closing price of $6.45. A 52-week range for AQST has been $2.12 – $7.55.
During the last 5-year period, the sales growth of Healthcare Sector giant was 27.90%. When this article was written, the company’s average yearly earnings per share was at -21.79%. With a float of $114.24 million, this company’s outstanding shares have now reached $121.66 million.
Aquestive Therapeutics Inc (AQST) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Aquestive Therapeutics Inc stocks. The insider ownership of Aquestive Therapeutics Inc is 6.36%, while institutional ownership is 51.21%. The most recent insider transaction that took place on Nov 17 ’25, was worth 286,209. Before that another transaction happened on Oct 15 ’25, when Company’s Chief Operating Officer sold 67,575 for $7.01, making the entire transaction worth $473,701. This insider now owns 240,771 shares in total.
Aquestive Therapeutics Inc (AQST) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.16 earnings per share (EPS) during the time that was less than consensus figure (set at -0.13) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 28.55% during the next five years compared to 27.90% growth over the previous five years of trading.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
You can see what Aquestive Therapeutics Inc (AQST) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of Aquestive Therapeutics Inc (AQST)
Looking closely at Aquestive Therapeutics Inc (NASDAQ: AQST), its last 5-days average volume was 2.74 million, which is a drop from its year-to-date volume of 2.81 million. As of the previous 9 days, the stock’s Stochastic %D was 76.90%.
During the past 100 days, Aquestive Therapeutics Inc’s (AQST) raw stochastic average was set at 65.45%, which indicates a significant increase from 63.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.29 in the past 14 days, which was lower than the 0.35 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.13, while its 200-day Moving Average is $4.46. However, in the short run, Aquestive Therapeutics Inc’s stock first resistance to watch stands at $6.41. Second resistance stands at $6.59. The third major resistance level sits at $6.70. If the price goes on to break the first support level at $6.11, it is likely to go to the next support level at $6.00. Should the price break the second support level, the third support level stands at $5.82.
Aquestive Therapeutics Inc (NASDAQ: AQST) Key Stats
There are 122,003K outstanding shares of the company, which has a market capitalization of 760.08 million. As of now, sales total 57,560 K while income totals -44,140 K. Its latest quarter income was 12,810 K while its last quarter net income were -15,450 K.
